Editorial: The individualization of antiplatelet therapy in coronary artery disease: escalation or de-escalations
Status PubMed-not-MEDLINE Jazyk angličtina Země Švýcarsko Médium electronic-ecollection
Typ dokumentu úvodníky
PubMed
37346282
PubMed Central
PMC10280152
DOI
10.3389/fcvm.2023.1219689
Knihovny.cz E-zdroje
- Klíčová slova
- antiplatelet therapy, colchicine, coronary artery disease, de-escalation, ethnicity, individualization,
- Publikační typ
- úvodníky MeSH
Zobrazit více v PubMed
Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. (2021) 42(14):1289–367. 10.1093/eurheartj/ehaa575 PubMed DOI
Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation. (2022) 145(3):e4–e17. 10.1161/CIR.0000000000001039 PubMed DOI
Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the academic research consortium for high bleeding risk. Eur Heart J. (2019) 40:2632–53. 10.1093/eurheartj/ehz372 PubMed DOI PMC
Laudani C, Greco A, Occhipinti G, Ingala S, Calderone D, Scalia L, et al. Short duration of DAPT versus De-escalation after percutaneous coronary intervention for acute coronary syndromes. JACC Cardiovasc Interv. (2022) 15(3):268–77. 10.1016/j.jcin.2021.11.028 PubMed DOI
Kang J, Rizas KD, Park KW, Chung J, van den Broek W, Claassens DMF, et al. Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis. Eur Heart J. (2023) 44(15):1360–70. 10.1093/eurheartj/ehac829 PubMed DOI
Jeong YH. “East Asian paradox”: challenge for the current antiplatelet strategy of “one-guideline-fits-all races” in acute coronary syndrome. Curr Cardiol Rep. (2014) 16(5):485. 10.1007/s11886-014-0485-4 PubMed DOI
Kim HK, Tantry US, Smith SC, Jeong MH, Park SJ, Kim MH, et al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost. (2021) 121:422–32. doi: 10.1055/s-0040-1718729 PubMed DOI
Gorog DA, Jeyalan V, Markides RIL, Navarese EP, Jeong YH, Farag M. Comparison of De-escalation of DAPT intensity or duration in East Asian and Western patients with ACS undergoing PCI: a systematic review and meta-analysis. Thromb Haemost. (2023). 10.1055/s-0043-57030. [Epub ahead of print] PubMed DOI
Mayer K, Bernlochner I, Braun S, Schulz S, Orban M, Morath T, et al. Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry. J Am Coll Cardiol. (2014) 64(9):863–71. 10.1016/j.jacc.2014.05.049 PubMed DOI
Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. (2019) 381(26):2497–505. 10.1056/NEJMoa1912388 PubMed DOI
Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. (2020) 383(19):1838–47. 10.1056/NEJMoa2021372 PubMed DOI
